Organon & Co. (OGN): Price and Financial Metrics

Organon & Co. (OGN): $18.00

0.18 (+1.01%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

OGN Price/Volume Stats

Current price $18.00 52-week high $24.79
Prev. close $17.82 52-week low $10.84
Day low $17.79 Volume 1,551,049
Day high $18.11 Avg. volume 2,759,035
50-day MA $17.96 Dividend yield 6.27%
200-day MA $17.22 Market Cap 4.60B

OGN Stock Price Chart Interactive Chart >


Organon & Co. (OGN) Company Bio


Organon & Co. Organon & Co. is a science-based global pharmaceutical company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. Its women's health portfolio includes Nexplanon or Implanon NXT, which is a patented long-acting reversible contraceptive. Its operating segments include the Organon Products segment. The Organon Products segment is engaged in developing and delivering health solutions through its portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's products segment portfolio includes: Women's Health, Biosimilars and Established Brands. Women's Health contains contraception and fertility brands, such as Nexplanon or Implanon NXT, NuvaRing and elonva. The Company's Biosimilars portfolio consists of three immunology products: Brenzys, Renflexis and Hadlima; and two oncology products: Ontruzant and Aybintio.


OGN Latest News Stream


Event/Time News Detail
Loading, please wait...

OGN Latest Social Stream


Loading social stream, please wait...

View Full OGN Social Stream

Latest OGN News From Around the Web

Below are the latest news stories about ORGANON & CO that investors may wish to consider to help them evaluate OGN as an investment opportunity.

Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference

JERSEY CITY, N.J., December 21, 2023--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference, Tuesday January 9.

Yahoo | December 21, 2023

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

JERSEY CITY, N.J., December 18, 2023--Organon becomes the sole distributor and promoter of Emgality® (galcanezumab) and RAYVOW™ (lasmiditan) in Europe

Yahoo | December 18, 2023

Organon To Present at the Piper Sandler 35th Annual Healthcare Conference

JERSEY CITY, N.J., November 21, 2023--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 11:00 a.m. EST.

Yahoo | November 21, 2023

Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®

sBLA based on Phase 4 study which assessed pharmacokinetic similarity between two treatment groups: multi-switching group alternating between Humira and high-concentration HADLIMA vs. Humira-continued groupFiling acceptance reinforces Samsung Bioepis and Organon’s commitment to provide better access to biologic medicines for patients in the United States INCHEON, South Korea and JERSEY CITY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today ann

Yahoo | November 7, 2023

Organon Reports Results for the Third Quarter Ended September 30, 2023

JERSEY CITY, N.J., November 02, 2023--Organon Reports Results for the Third Quarter Ended September 30, 2023

Yahoo | November 2, 2023

Read More 'OGN' Stories Here

OGN Price Returns

1-mo 1.24%
3-mo 12.33%
6-mo 19.71%
1-year -20.27%
3-year N/A
5-year N/A
YTD 26.74%
2023 -45.12%
2022 -4.86%
2021 N/A
2020 N/A
2019 N/A

OGN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full OGN Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!